Target intelligence / Profile preview

Fragile X mental retardation, autosomal homolog 1 pseudogene

Molecular classification: Pseudogene

Overview

Fragile X mental retardation, autosomal homolog 1 pseudogene (ENSG00000257376) is a non-coding genomic locus that resembles the FXR1 gene, but has accumulated mutations (such as frameshifts or premature stop codons) making it incapable of encoding a functional protein[1]. Pseudogenes are typically regarded as "genomic fossils" but may, in some cases, display regulatory functions by acting as competitive endogenous RNAs (ceRNAs), sponging microRNAs and thereby influencing the expression of their parent gene or other transcripts[4][7]. However, direct functional or therapeutic relevance for this particular pseudogene has not been documented[1][4]. Most pseudogenes, including this one, are not considered therapeutic targets due to their lack of protein product and established functional role.

Other names: FXR1 pseudogene

Biological functions

Possible microRNA decoy activity (as reported for other pseudogenes, e.g., PTENP1; pseudogenes can regulate their parent genes by competing for microRNA binding, though evidence for FXR1P specifically is lacking)May participate in regulatory mechanisms at the RNA level (if transcribed), including possible microRNA sponge or decoy activities

Disease associations

Not directly involved in disease (no evidence for this specific pseudogene); however, pseudogenes in general can act as regulators affecting disease progression indirectly by altering expression of their parent genes (shown for PTENP1 and KRAS1P, but not FXR1P)FXR1 gene (the protein-coding counterpart) is associated with roles in muscular and neurological function—but the pseudogene is not directly implicated in disease.

Beyond the preview

Go deeper on Fragile X mental retardation, autosomal homolog 1 pseudogene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fragile X mental retardation, autosomal homolog 1 pseudogene.

Explore the full profile